Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Intratympanic N-Acetylcysteine Cisplatin Otoprotection Studies

Also known as: N-Acetyl Cysteine, NAC, Lysomucil 10%, Intratympanic NAC, NCT04291209, NCT04226456

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 4

Status

Unknown

Target Gene

—

Route / Mode

Intratympanic injection

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Belgium, Canada

Population

adult, cisplatin-ototoxicity, tinnitus, bilateral

Trial IDs

Mechanism

Registry-backed institution-led studies evaluating intratympanic N-acetylcysteine before cisplatin chemotherapy to prevent or reduce cisplatin-induced ototoxic hearing loss.

Indications

Hearing Loss Cisplatin-Induced Hearing Loss Tinnitus

Notes

Verified as a two-study academic NAC otoprotection cluster. NCT04291209 has registry status Unknown after a passed estimated completion date; NCT04226456 terminated. This should be presented as registry-backed study evidence, not a current commercial NAC product program.

Evidence & Sources

2 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT04291209

Open

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT04226456

Open

Key Events

2020-02-26